BioWorld

June 2, 2005

View Archived Issues

BioMarin's Second MPS Drug, Naglazyme, Approved By FDA

BioMarin Pharmaceutical Inc. is wasting little time getting to the market with its newly approved enzyme-replacement therapy, Naglazyme, for patients with mucopolysaccharidosis VI. (BioWorld Today) Read More

Hybridon, Novartis In $136M Agreement For TLR9 Drugs

Read More

Affymetrix Buys Out Partner ParAllele: $120M Stock Deal

Read More

Intra-Cellular Paying BMS For License To CNS Drugs

Read More

Other News To Note

Read More